These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 10409442

  • 1. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR, Liu W, Smith ST, Parrish RS, Young SR.
    Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
    [Abstract] [Full Text] [Related]

  • 2. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
    Afify AM, Werness BA, Mark HF.
    Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
    [Abstract] [Full Text] [Related]

  • 3. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.
    Cancer; 2005 Oct 01; 104(7):1391-7. PubMed ID: 16116605
    [Abstract] [Full Text] [Related]

  • 4. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
    Persons DL, Borelli KA, Hsu PH.
    Mod Pathol; 1997 Jul 01; 10(7):720-7. PubMed ID: 9237184
    [Abstract] [Full Text] [Related]

  • 5. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.
    Young SR, Liu WH, Brock JA, Smith ST.
    Genes Chromosomes Cancer; 1996 Jun 01; 16(2):130-7. PubMed ID: 8818660
    [Abstract] [Full Text] [Related]

  • 6. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array.
    Rummukainen JK, Salminen T, Lundin J, Kytölä S, Joensuu H, Isola JJ.
    Mod Pathol; 2001 Oct 01; 14(10):1030-5. PubMed ID: 11598174
    [Abstract] [Full Text] [Related]

  • 7. Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization.
    Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M, Tanaka S.
    Ann Thorac Cardiovasc Surg; 2001 Aug 01; 7(4):197-203. PubMed ID: 11578259
    [Abstract] [Full Text] [Related]

  • 8. Fluorescence in situ hybridization analysis of c-myc amplification in stage TNM prostate cancer in Japanese patients.
    Sato H, Minei S, Hachiya T, Yoshida T, Takimoto Y.
    Int J Urol; 2006 Jun 01; 13(6):761-6. PubMed ID: 16834657
    [Abstract] [Full Text] [Related]

  • 9. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.
    Williams JA, Wang ZR, Parrish RS, Hazlett LJ, Smith ST, Young SR.
    Exp Mol Pathol; 1999 Dec 01; 67(3):135-43. PubMed ID: 10600396
    [Abstract] [Full Text] [Related]

  • 10. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
    Riben MW, Malfetano JH, Nazeer T, Muraca PJ, Ambros RA, Ross JS.
    Mod Pathol; 1997 Aug 01; 10(8):823-31. PubMed ID: 9267826
    [Abstract] [Full Text] [Related]

  • 11. Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.
    Persons DL, Hartmann LC, Herath JF, Borell TJ, Cliby WA, Keeney GL, Jenkins RB.
    Am J Pathol; 1993 Mar 01; 142(3):733-41. PubMed ID: 8096121
    [Abstract] [Full Text] [Related]

  • 12. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
    Shimada M, Imura J, Kozaki T, Fujimori T, Asakawa S, Shimizu N, Kawaguchi R.
    Oncol Rep; 2005 Apr 01; 13(4):633-41. PubMed ID: 15756435
    [Abstract] [Full Text] [Related]

  • 13. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
    Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
    Cancer Res; 1995 Dec 01; 55(23):5693-8. PubMed ID: 7585656
    [Abstract] [Full Text] [Related]

  • 14. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y, Soslow RA, Marshall DS, Leitao M, Chen B.
    Gynecol Oncol; 2004 Dec 01; 95(3):570-5. PubMed ID: 15581965
    [Abstract] [Full Text] [Related]

  • 15. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.
    Isola J, Tanner M, Forsyth A, Cooke TG, Watters AD, Bartlett JM.
    Clin Cancer Res; 2004 Jul 15; 10(14):4793-8. PubMed ID: 15269154
    [Abstract] [Full Text] [Related]

  • 16. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D, Haffty BG.
    Clin Cancer Res; 2002 Feb 15; 8(2):540-8. PubMed ID: 11839675
    [Abstract] [Full Text] [Related]

  • 17. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
    Grushko TA, Blackwood MA, Schumm PL, Hagos FG, Adeyanju MO, Feldman MD, Sanders MO, Weber BL, Olopade OI.
    Cancer Res; 2002 Mar 01; 62(5):1481-8. PubMed ID: 11888924
    [Abstract] [Full Text] [Related]

  • 18. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.
    Mark HF, Feldman D, Das S, Kye H, Mark S, Sun CL, Samy M.
    Exp Mol Pathol; 1999 Jun 01; 66(2):170-8. PubMed ID: 10409446
    [Abstract] [Full Text] [Related]

  • 19. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade.
    Mahdy E, Pan Y, Wang N, Malmström PU, Ekman P, Bergerheim U.
    Anticancer Res; 2001 Jun 01; 21(5):3167-73. PubMed ID: 11848469
    [Abstract] [Full Text] [Related]

  • 20. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization.
    Jenkins RB, Qian J, Lieber MM, Bostwick DG.
    Cancer Res; 1997 Feb 01; 57(3):524-31. PubMed ID: 9012485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.